Dowiedzieć się o najlepszych cenach i klinikach w usunięciu guza trzustki w Izraelu w 2026 roku

Prof. Ofer Merimsky kieruje Jednostką Onkologii Ortopedycznej w Centrum Medycznym Sourasky, posiadając ponad 25 lat doświadczenia w specjalizacji w złożonym leczeniu mięsaków.

• Profesor nadzwyczajny, specjalizujący się w nowotworach tkanek miękkich i kości
• Odbył szkolenie (fellowship) z zakresu mięsaków w Institut Gustave Roussy (Paryż)
• Członek kadry dydaktycznej ESMO ds. mięsaków tkanek miękkich i kości
• Opublikowane badania dotyczące immunologii nowotworów i onkogenetyki

Dr. Arnon Nagler is a hematologist at Sheba Medical Center in Israel. He is a professor at Tel Aviv University and a renowned transplant expert. Dr. Nagler founded Israel’s first public cord blood bank. He also performed the first cord blood transplantations in the country. He completed postdoctoral training at Stanford University and is board-certified in hematology.

• Pioneered reduced–intensity allogeneic transplant protocols for blood cancers.
• Served as Chair of the Acute Leukemia Working Party for the EBMT.
• Published over 400 articles in leading journals like Blood and Leukemia.
• Works at Sheba Medical Center, ranked 7th worldwide by Newsweek in 2026.

Dr. Almog Ben Yaacov is a senior surgical oncologist at Sheba Medical Center. He has performed over 200 HIPEC procedures for complex abdominal cancers. He focuses on treating gastric cancer, sarcoma, and colorectal malignancies. Dr. Ben Yaacov holds board certifications in both General Surgery and Surgical Oncology.

• Completed surgical oncology training at Memorial Sloan Kettering in New York.
• Uses NanoKnife and microwave liver ablation for targeted tumor treatment.
• Maintains ESSO certification for cytoreductive surgery and HIPEC.
• Works at Sheba Medical Center, ranked among the world’s top 10 hospitals.

Dr. Amit Tirosh is the Head of the Neuroendocrine Tumors (NET) Service at Sheba Medical Center. He is an international authority on von Hippel–Lindau (VHL) disease and hereditary tumor syndromes. Dr. Tirosh contributed to global clinical guidelines for VHL management. He also leads the Endocrine Oncology Bioinformatics Lab at Sheba.

• Contributor to the international expert panel on VHL management guidelines.
• Authored over 40 peer-reviewed papers in journals like JAMA and Gastroentrology.
• Maintains research affiliations with the NIH and the Weizmann Institute.
• Performs specialized NET treatments, including Lutetium-177 therapy and PRRT.